Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr O’Brien on the Potential Role for Noncovalent BTK Inhibitors in MCL and CLL

July 13th 2023

Susan M. O’Brien, MD, discusses the potential role for noncovalent BTK inhibitors in the treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Dr O’Brien on the Use of Pirtobrutinib in BTK Inhibitor-Resistant MCL and CLL

June 30th 2023

Susan M. O’Brien, MD, discusses the use of pirtobrutinib for patients with hematologic malignancies who developed resistance to BTK inhibition.

Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma

June 27th 2023

As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.

Dr Ahmed on Real-World Findings With Brexu-Cel in MCL

June 21st 2023

Nausheen Ahmed, MD, discusses findings from a real-world subgroup analysis of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Preliminary Efficacy of Acalabrutinib Plus BR in MCL

June 20th 2023

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

June 19th 2023

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Sustained Clinical Benefit in Mantle Cell Lymphoma

June 19th 2023

The combination of ibrutinib, obinutuzumab, and venetoclax was associated with prolonged survival in patients with newly diagnosed or relapsed/refractory mantle cell lymphoma.

Dr Shah on Long-Term Survival Data For Pirtobrutinib in BTK Inhibitor–Pretreated R/R MCL

June 16th 2023

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

June 15th 2023

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Real-World Analysis Supports Use of Brexu-Cel in Relapsed/Refractory MCL

June 15th 2023

The real-world efficacy and safety of brexucabtagene autoleucel were similar to the outcomes seen in the phase 2 ZUMA-2 trial, regardless of patients’ treatment history, according to results from a real-world subgroup analysis of patients with relapsed/refractory mantle cell lymphoma.

Dr Kambhampati on the Real-world Efficacy of Brexu-Cel in Heavily Pretreated Patients With MCL

June 13th 2023

Swetha Kambhampati, MD, discusses key findings from an analysis of real-world efficacy outcomes with brexucabtagene autoleucel in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL

June 9th 2023

The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Investigation of Acalabrutinib/Benendamustine/Rituximab in MCL

June 7th 2023

Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

May 23rd 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on Treatment After Progression on a BTK Inhibitor in MCL

May 22nd 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

May 19th 2023

Polymorphic alleles of ABCB1 or VEGF were predictive of lenalidomide efficacy in patients with mantle cell lymphoma who received lenalidomide maintenance after autologous stem cell transplant.

Dr Habermann on Ongoing Trials in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.